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http://dx.doi.org/10.1016/j.bgm.201
2214-0247/Copyright ª 2014, TaiwanAbstract We investigated the concentrations of transforming growth factor b1 (TGF-b1) and
a smooth muscle actin (a-SMA) in the urine of a group of patients with lupus nephritis with
renal fibrosis (LNF) and a group of patients with lupus nephritis without renal fibrosis (LN).
Forty-five patients in the group with LNF, 13 patients in the group with LN, and 32 healthy con-
trols took part in the study. The diagnosis of lupus nephritis was made according to the Amer-
ican College of Rheumatology criteria and the histopathology. A renal biopsy sample was taken
from all patients with lupus to measure the chronicity index and the percentage of fibrosis. The
concentrations of TGF-b1 and a-SMA were measured in urine samples by enzyme-linked immu-
nosorbent assay. The percentage of patients with a chronicity index 4 was higher in the group
with LNF (31.0%) than in the group with LN (0%). The percentage of patients with fibrosis 5%
was higher in the group with LNF (44.3%). The concentration of TGF-b1 was significantly lower
in patients with a chronicity index <4 than in patients with a chronicity index 4 (p < 0.05). In
addition, the concentration of TGF-b1 in urine samples was significantly higher in the group
with fibrosis 5% than the group with fibrosis <5% (p < 0.05). There was a significant positive
correlation between the concentration of TGF-b1 in urine samples and the chronicity index
(r Z 0.606; p < 0.05) and the percentage of fibrosis (r Z 0.602; p < 0.05). However, there
was no significant difference between the concentration of a-SMA in the urine of patients withof Clinical Pathology, Faculty of Medicine Brawijaya University/Dr Saiful Anwar Hospital Malang, Jl.
ava, Indonesia.
o.com (H. Susianti).
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26 H. Susianti et al.a chronicity index <4 or those with a chronicity index 4 (p > 0.05) or in patients with a per-
centage of fibrosis 5% and those with fibrosis <5% (p > 0.05). In addition, there was no sig-
nificant correlation between a-SMA concentrations and the chronicity index (r Z 0.073;
p > 0.05) or the percentage of fibrosis (r Z 0.091; p > 0.05). The sensitivity, specificity,
and negative predictive value of TGF-b1 were higher than those of a-SMA. In conclusion, the
concentration of TGF-b1 in urine samples was a better biomarker of renal fibrosis in patients
in the group with LN than the concentration of a-SMA.
Copyright ª 2014, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
Systemic lupus erythematosus (SLE) is a systemic autoim-
mune disease common in women of childbearing age. SLE
results in impaired function of various body systems and has
a high mortality rate, especially in developing countries.
The five-year survival rate of patients with SLE in Indonesia
is 70% and the life expectancy 10 years after diagnosis is
50%.1 One serious manifestation of the SLE is lupus
nephritis, which occurs in 40e60% of patients with SLE and
can result in kidney failure or end-stage renal disease.2
The prognosis for Asian and African patients with lupus
nephritis is poorer than that for patients of other ethnic-
ities.2 One of the reasons for this is that early detection and
monitoring of the progression of the disease is difficult. The
gold standard of detection, a renal biopsy sample, is inva-
sive, expensive, and requires special equipment and
expertise. It is therefore difficult to implement, particu-
larly in developing countries. There is thus a need to find
new, non-invasive biological markers for the early detec-
tion and monitoring of the progression of lupus nephritis.
The main feature of end-stage renal disease is renal
fibrosis, in which transforming growth factor b1 (TGF-b1)
and a smooth muscle actin (a-SMA) play important parts.
Renal fibrosis was previously thought to be a static state that
could not be repaired, but recent research has succeeded in
inducing regression.3 Previous studies have concluded that
treatment with angiotensin-converting enzyme inhibitors
significantly increases the number of podocytes in the
glomerulus, resulting in an improvement in the degree of
renal fibrosis.4 It is therefore necessary to understand the
mechanisms of this improvement in renal fibrosis for good
patient management and to increase the life expectancy of
patients. The search for a biological marker to monitor the
progression or response to treatment of patients with renal
fibrosis is important in achieving these aims.
Previous studies have shown an increased expression of
TGF-b1 in the kidneys and urine of patients with crescentic
nephritis, which is associated with fibrosis.5 However, the
results of other studies have indicated that TGF-b1 mRNA
expression in urine samples is not significantly correlated
with fibrosis. The role of TGF-b1 as a biomarker for renal
fibrosis remains controversial, indicating the need for
further study.6,7 In normal kidneys, the expression of a-SMA
is limited to the vascular smooth muscle cells. In patho-
logical conditions, however, a-SMA is expressed in glomer-
ular mesangial cells and myofibroblasts. Myofibroblasts thatexpress a-SMA are responsible for the increased amount of
extracellular matrix and fibrosis.8 Therefore the aim of this
study was to investigate the concentrations of TGF-b1 and
a-SMA in the urine of patients with lupus nephritis with
renal fibrosis (LNF group) and in patients with lupus
nephritis without renal fibrosis (LN group).
Materials and methods
Patients
Forty-five patients in the LNF group, 13 patients in the LN
group, and 32 healthy controls took part in this study. The
diagnosis of lupus nephritis was made according the
American Collage Rheumatology 1997 criteria and on the
basis of the histopathology. A renal biopsy sample was
taken for all patients with lupus nephritis.
Urine sampling
Urine samples were taken to find the concentrations of
TGF-b1 and a-SMA. Morning urine samples were collected
aseptically in sterile containers, centrifuged immediately,
and stored at 80C until analysis.
Determination of TGF-b1, a-SMA, serum
creatinine, and proteinuria in urine samples
The urine concentrations of TGF-b1 were measured by
sandwich enzyme-linked immunosorbent assay using the
Quantikine human TGF-b1 kit (R & D, Minneapolis, MN,
USA). The concentrations of a-SMA in urine were measured
by sandwich enzyme-linked immunosorbent assay using kits
from Ausmausco Pharma Co. Ltd (Shanghai, China). Serum
creatinine concentrations and proteinuria were determined
using a kit from Roche (New York, NY, USA) according to the
manufacturer’s protocol.
Determination of fibrosis
The fibrosis scoring was based on the chronicity index and
percentage of fibrosis. The tissues were stained using hema-
toxylineeosin, periodic acideSchiff, and Masson’s trichrome.
Morphometric analysis was used to assess the percentage of
fibrosis in the renal tissue. Digital images of the sectionswere
photographed using an Olympus microscope (Olympus,
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ment of fibrosis was carried out using C5S Adobe Photoshop
(Adobe Systems Corporation, San Jose, CA, USA).9 The per-
centage of fibrosis was obtained by dividing the blue area
(fibrotic tissue) by the total area expressed in pixels. Patients
with lupus nephritis with a percentage of fibrosis 5% were
categorized as normal state because normal kidney tissue
consists of extracellular matrix. The histopathological chro-
nicity index of lupus nephritis was determined by theNational
Institutes of Health criteria and was assessed by two pathol-
ogists. The final scores were obtained by adding all the scores
from each of the following parameters: glomerular sclerosis,
crescent fibrous structure, tubular atrophy, and interstitial
fibrosis. Scores obtained from this assessment added up to
between 1 and 12. Patients with a low chronicity index (<4)
have a better therapeutic response than patients with a high
chronicity index (4).10
Ethics
This research was approved by the Research Ethics Com-
mittee of the Faculty of Medicine, University of Brawijaya,
Malang, Indonesia. Informed consent was obtained from all
patients included in this study.
Statistical analysis
The data are presented as mean  SD values and the dif-
ferences between groups were analyzed using the Student t
test or the ManneWhitney test with SPSS version 17.0 sta-
tistical package (SPSS Inc., Chicago, IL, USA). The analysis
of sensitivity, specificity, positive predictive value, nega-
tive predictive value, receiver operating characteristics,
and area under the receiver operating characteristics curve
were performed with the SPSS 17.00 statistical package.
Assessment of the area under the receiver operating char-
acteristics curve was categorized into outstanding
(0.9e1.0), excellent (0.81e0.90), good (0.71e0.80), fair
(0.61e0.70), or poor (0.50e0.60).11
Results
Table 1 shows that the most patients with lupus nephritis
were women of childbearing age. The age and sexTable 1 Demographic and clinical characteristics of patients in
Parameter Healthy controls (n Z
Age (y) 30.00  3.12
Sex
Female 29 (90.62)
Male 3 (9.37)
Duration of illness (mo) d
Drug treatment
Prednisolone d
Immunosuppressive drugs d
Data are presented as mean  SD values or n (%).
LNZ group of patients with lupus nephritis without renal fibrosis; LNF
was no significant difference between the three groups.distributions were not significantly different between
groups (p > 0.05). The length of illness in the LNF group was
19.83  10.33 months, whereas the length of illness in the
LN group was 15.53  11.89 months (p > 0.05).
Table 2 presents the concentrations of several bio-
markers in all three groups. We found significantly different
concentrations of serum creatinine, proteinuria, and con-
centrations of TGF-b1 and a-SMA in urine samples in the
patient groups compared with the control group (p < 0.05).
Table 3 gives the chronicity index and the percentage of
fibrosis. The number of patients with a chronicity index 4
was higher in the LNF group (31.0%) than in the LN group
(0%). A percentage of fibrosis >5% was dominant in LNF
group (44.3%).
Table 4 shows that there was a significant positive cor-
relation between the concentrations of TGF-b1 in urine
samples and the chronicity index (r Z 0.606; p < 0.05) and
the percentage of fibrosis (r Z 0.602; p < 0.05). There was
no significant correlation between the concentration of a-
SMA and the chronicity index (r Z 0.073; p > 0.05) or the
percentage of fibrosis (rZ 0.091; p > 0.05). In addition, the
concentrations of TGF-b1 were significantly lower (p < 0.05)
in the group with a chronicity index <4 (39.82  32.55 pg/
mL) than in the groups with a chronicity index 4
(134.51  31.55 pg/mL). The concentrations of TGF-b1 were
significantly higher in the group with renal fibrosis >5%
(49.80  30.25 pg/mL) than in the group with renal fibrosis
5% (34.80  33.34 pg/mL). There was no significant dif-
ference (p > 0.05) between the concentration of a-SMA in
the group with a chronicity index <4 (323.33  210.12 pg/
mL) compared with the group with a chronicity index 4
(569.67  679.75 pg/mL) or in the group with >5% renal
fibrosis (495.30  605.60 pg/mL) compared with the group
with 5% renal fibrosis (319.41  230.84 pg/mL).
Fig. 1 shows that area under the curve for TGF-b1 was
better than that for a-SMA in urine samples. The calculated
area under the curve was 0.9 for TGF-b1 in urine samples
(cutoff point 27.78 pg/mL) and 0.48 for a-SMA in urine
samples (cutoff point 244.00 pg/mL).
The sensitivity, specificity, and negative predictive value
of TGF-b1 were higher than those of a-SMA. The sensitivity
and positive predictive value of the combined TGF-b1 and
a-SMA concentrations were higher than those of TGF-b1 or
a-SMA alone, but the specificity and negative predictive
values were lower (Table 5).this study.
32) LN (n Z 13) LNF (n Z 45)
30.61  9.55 28.18  8.58
13 (100) 42 (93.33)
0 (0.00) 3 (6.66)
15.53  11.89 19.83  10.33
13 (100) 45 (100)
10 (76.92) 28 (62.22)
Z group of patients with lupus nephritis with renal fibrosis. There
Table 2 Concentrations of serum creatinine, proteinuria, and TGF-b1 and a-SMA urine samples from all patient groups.
Biomarker Healthy controls (n Z 32) LN (n Z 13) LNF (n Z 45)
Serum creatinine (mg/dL) 0.61  0.11 0.55  0.123 1.56  0.92*,**
Proteinuria (mg/dL) 39.77  37.00 100.87  73.35 753.82  702.78*,**
TGF-b1 in urine (pg/mL) 23.89  11.00 23.14  6.59 63.80  90.12*,**
a-SMA in urine (pg/mL) 158  80.59 344.61  234.44* 415.71  467.58*
Data are presented as mean  SD values or n (%).
*p < 0.05 compared with the healthy control group.
**p < 0.05 compared with the LN group.
a-SMA Z a smooth muscle actin; LN Z group with lupus nephritis without renal fibrosis; LNF Z group with lupus nephritis with renal
fibrosis; TGF-b1 Z transforming growth factor b1.
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Some studies of TGF-b1 as a biomarker have been carried
out by measuring the mRNA expression of TGF-b1 and the
concentrations of the TGF-b1 cytokine in urine samples.
Urine is a good candidate for a lupus nephritis biomarker.12
Biomarkers in urine are produced in the kidneys andTable 3 Chronicity index scores and percentage of renal
fibrosis in patients with lupus nephritis.
Parameter LN LNF Total
Chronicity index score (n Z 58)
0 13 (22.41) 0 (0) 13 (22.41)
<4 0 27 (46.55) 27 (46.55)
4 0 18 (31.03) 18 (31.03)
% of renal fibrosis (n Z 52)
5 13 (25.00) 16 (30.76) 29 (55.76)
>5 0 (0) 23 (44.23) 23 (44.23)
Data are presented as n (%) of patients.
LN Z group with lupus nephritis without renal fibrosis;
LNF Z group with lupus nephritis with renal fibrosis.
Table 4 Correlation of TGF-b1 or a-SMA concentrations in
urine samples with chronicity index, percentage of renal
fibrosis, serum creatinine concentration, and proteinuria.
Parameter Correlation
coefficient (r)
p
TGF-b1 concentration in urine samples (pg/mL)
Chronicity index 0.606 <0.001*
Percentage with renal fibrosis 0.602 <0.001*
Serum creatinine
concentration (mg/dL)
0.522 <0.001*
Proteinuria (mg/dL) 0.432 <0.001*
a-SMA concentration in urine samples (pg/mL)
Chronicity index 0.073 0.58
Percentage with renal fibrosis 0.091 0.52
Serum creatinine
concentration (mg/dL)
0.164 0.12
Proteinuria (mg/dL) 0.347 <0.001*
*p < 0.05.
a-SMAZ a smooth muscle actin; TGF-b1Z transforming growth
factor b1.possibly have a direct role in the pathogenesis of renal
injury.13 The determination of urinary biomarkers is ex-
pected to replace renal biopsy samples because they are
more simple, secure, and accurate, and can be performed
repeatedly to follow the progression of a disease and to
monitor the response to treatment.14
The results of our study showed that there are significant
differences in the concentrations of urinary TGF-b1 be-
tween the LNF and LN groups. However, there were also
significant differences in the concentrations of urinary TGF-
b1 between the LNF and healthy control groups. Unfortu-
nately, data from the patients with SLE without nephritis
could not be analyzed statistically because only three kid-
ney biopsy samples were obtained during sample collection
between 2011 and 2013. Our results are consistent with
previous research that found an increase in the expression
of TGF-b1 in renal tissue and in the urinary concentration of
TGF-b1 in patients with crescentic nephritis associated with
fibrosis.5
Previous studies have shown that the urinary excretion
of TGF-b1 is higher in patients with an obstructive uropathy
than in those with glomerulopathy.15 This finding was a
result of the increase in TGF-b1 in epithelial mesenchymal
transformation and post-obstructive tubulointersisial
fibrosis. There is an excessive production of TGF-b1 from
invasive inflammatory cells and tubular epithelial cell
activation. TGF-b1 is one of the key mediators of tubu-
lointerstitial fibrosis, epithelial cell apoptosis, and atrophy
of tubular cells after renal obstruction. A rat lupus model
has shown that increased TGF-b1 expression in kidneys
leads to progressive organ damage. Concentrations of TGF-
b1 in renal tissue and urine samples are correlated with the
expansion of chronic lesions that appear as tissue fibrosis,
but are not correlated with inflammation.16 Administrating
an antibody against TGF-b1 inhibits the formation of
chronic fibrotic lesions, but has no visible effect on local
inflammation and autoantibody production. The Saxena
et al. research show that the function of TGF-b1 is
different; in the early stages of disease TGF-b1 plays a part
in autoimmune disorders, whereas in the later stages TGF-
b1 causes organ damage in systemic autoimmune inflam-
matory diseases such as lupus. Increased renal production
of TGF-b1 is thought to be caused by the infiltration of
leukocytes into renal cells, which respond by producing
TGF-b1 to address the inflammation that has occurred and
to initiate tissue repair processes, but then progress into a
chronic process that leads to fibrosis. Previous animal
Figure 1 Receiver operating characteristic (ROC) curves of TGF-b1 and a-SMA. The fraction of true positive results (sensitivity)
and false positive results (1 e specificity) for (A) TGF-b1 in urine samples and (B) a-SMA in urine samples. The calculated area under
the curve was 0.9 for TGF-b1 in urine samples (cutoff point 27.78 pg/mL) and 0.48 for a-SMA in urine samples (cutoff point
244.00 pg/mL).
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marker for fibrogenesis to identify the phased progression
of advanced renal disease.16 Our study showed that the
disease process is a chronic condition that supports the
occurrence of renal fibrosis. Urinary TGF-b1 concentrations
in our study were significantly different between patients
with high and low chronicity indices and between patients
with a high and low percentage of renal fibrosis. This sug-
gests that the more severe the renal fibrosis, the higher the
concentration of TGF-b1 in urine samples.
Immunosuppressive treatment is known to limit damage
to the glomerulus during the formation of cellular cres-
cents, whereas it is possible that permanent damage may
occur with further fibrosis. Patients who experienced a
significant improvement in their renal function and were
treated with immunosuppressive drugs had a significantly
lower excretion of TGF-b1 in urine than patients who did
not show an improvement in renal function. These results
indicate that the measurement of urinary TGF-b1 at a
particular stage in the course of the disease may be useful
in predicting the progression of end-stage renal disease and
provide information via a non-invasive procedure withTable 5 Diagnostic value of TGF-b1 and a-SMA in urine
samples.
Diagnostic value TGF-b1 a-SMA TGF-b1
and a-SMA
Sensitivity (%) 84 55 91
Specificity (%) 85 46 46
Positive predictive value (%) 75 78 85
Negative predictive value (%) 81 23 60
Positive likelihood ratio 2.7 1.03 1.71
Negative likelihood ratio 0.22 0.95 0.17
a-SMAZ a smooth muscle actin; TGF-b1Z transforming growth
factor b1.which to monitor the response to treatment.5 Unfortu-
nately, in our study, we did not assess the response to
treatment by determining the concentrations of TGF-b1
longitudinally and therefore the changes in the concen-
trations of TGF-b1 with the treatment response could not
be followed. In our study, all the patients were treated with
prednisolone and >60% in the groups with LNF and LN
received treatment with immunosuppressive drugs. As the
patients in both groups received similar treatment, it is
expected that the results of this study were not
compromised.
The sensitivity, specificity, positive predictive value, and
negative predictive value of TGF-b1 were sufficient for the
diagnosis of renal fibrosis in patients with lupus nephritis.
There has been little research into determining the con-
centration of TGF-b1 as a biomarker for fibrosis in patients
with lupus nephritis. Previous studies have shown that
increased concentrations of TGF-b1 correlate with a poorer
prognosis of immunoglobulin A (IgA) nephropathy.6 In IgA
nephropathy, the kidney becomes sensitive to the action of
fibrogenic TGF-b1. This contributes to renal fibrosis that, in
turn, leads to kidney disease and decreased kidney func-
tion.17 Our study found increased concentrations of serum
creatinine and proteinuria in the groups with LNF and a high
concentration of TGF-b1. The sensitivity, specificity, and
negative predictive value of a-SMA for the diagnosis of
fibrosis were less than those of TGF-b1. These results are
consistent with previous research that found no relation
between the expression of a-SMA and the concentration of
creatinine and renal fibrosis.18 However, in other research,
interstitial a-SMA was correlated with the chronicity index
(p < 0.05), indicating that it could be used as a biomarker
for the prognosis of patients with lupus nephritis.19 This
difference may be due to many factors that influence the
concentration of a-SMA in urine, including antifibrotic cy-
tokines such as interleukin 12 and interferon gamma that
inhibit the differentiation of fibroblasts. Concentrations of
TGF-b1 combined with a-SMA in urine samples showed
30 H. Susianti et al.increased sensitivity and a positive predictive value, but
lower specificity and negative predictive values. This sug-
gests that the incorporation of these two biomarkers would
be useful in screening tests. The limitation of our study was
that the patients with SLE without nephritis could not be
analyzed, so further studies are needed with more
participants.
Conclusion
Our data have shown that the concentration of TGF-b1 in
urine samples have better sensitivity and specificity than
that of a-SMA. TGF-b1 is therefore a better biomarker of
renal fibrosis in patients with lupus nephritis.
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